Why the Botanix (ASX:BOT) share price is rocketing 31% higher today

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is rocketing 31% higher on Wednesday. Here’s what is happening…

| More on:
asx share price increase represented by golden dollar sign rocketing out from white domes of lithium

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price has returned from its trading halt with a bang on Wednesday.

In morning trade, the clinical stage synthetic cannabinoid company’s shares are up 31% to a record high of 19 cents.

Why is the Botanix share price rocketing higher?

Investors have been fighting to buy Botanix shares this morning following the release of an announcement in relation to its BTX 1801 Phase 2a nasal decolonisation proof of concept study.

According to the release, top-line data from the study shows that two different BTX 1801 formulations (ointment and gel containing synthetic cannabidiol) were safe, well tolerated, and successful at eradicating Staphylococcus aureus (Staph) bacteria from the nose of healthy participants that were nasally colonised with Staph.

The release explains that the primary objectives focused on evaluating safety and tolerability, as well as evaluating the effectiveness of two different candidate formulations of BTX 1801.

Each formulation was applied twice daily for five consecutive days to the inner surface of the nose and compared to respective vehicle or placebo formulations without synthetic cannabidiol.

At day seven, Staph eradication was demonstrated in 76.2% and 68.8% of the participants in the BTX 1801 ointment and gel groups respectively, compared with just 27.8% of participants in the combined vehicle groups.

On day 12, which was seven days after the end of the treatment period, BTX 1801 demonstrated Staph eradication in 38.1% of participants in the ointment group and 25% in the gel group. This compares to 16.7% for the combined vehicle groups.

Why is this important?

The company notes that antibiotic resistance is a significant global challenge in the context of public health. In fact, the UN is forecasting that drug resistant diseases could cause 10 million deaths each year by 2050 and result in an annual economic loss of US$100 trillion if new solutions are not found.

Furthermore, Staph and methicillin-resistant Staph (MRSA) are the leading cause of Surgical Site Infections (SSIs) and approximately 80% of SSIs are caused by the patient infecting themselves from their own nose.

Antibiotics used for nasal decolonisation, such as Bactroban, have seen a significant increase in the development of resistance, with some hospitals restricting its use after recording resistance rates as high as 95%.

This opens the door for new treatments to be developed to tackle these issues. Botanix appears hopeful synthetic cannabidiol could be the answer.

Botanix President and Executive Chairman, Vince Ippolito, commented: “We are very pleased to announce this top-line data that demonstrates synthetic cannabidiol (CBD) is a safe and effective nasal decolonisation agent. Moreover, this is the first time that synthetic CBD has been shown to have clinical utility as an antimicrobial agent in humans.”

“These results support continued development of BTX 1801 for the treatment of a variety of infections, in addition to the prevention of post-surgical infections,” he added.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why CSL, IPH, Renascor, and Treasury Wine shares are pushing higher

These ASX shares are having strong days. Here's why...

Read more »

Three children wearing athletic short and singlets stand side by side on a running track wearing medals around their necks and standing with their hands on their hips.
Share Gainers

3 tiny ASX mining shares leaping over 20% on project announcements

Why are these shares soaring today?

Read more »

a small boy dressed in a superhero outfit soars into the sky with a graphic backdrop of a cityscape.
Resources Shares

Guess which ASX lithium share just rocketed 20%

The Aussie-based lithium explorer is now the largest holder of lithium mining claims in the US state of South Dakota.

Read more »

Female miner smiling at a mine site.
Share Gainers

Why has the Mineral Resources share price surged 40% in a month?

What a month it has been for Mineral Resources shares.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Share Gainers

Why Brambles, Challenger, Nearmap, and Super Retail shares are rising today

These ASX shares are having strong days...

Read more »

Three women cruise along enjoying ice-creams in the sunshine.
Share Gainers

3 ASX 300 shares having a cracking session today

These ASX 300 shares are parading big gains today...

Read more »

Three happy shoppers.
Retail Shares

Why are ASX 200 retail shares having such a stellar run today?

ASX 200 retail shares are on fire today. What's put a rocket under this ASX 200 sector?

Read more »

Rocket powering up and symbolising a rising share price.
Share Gainers

Guess which tiny ASX mining share just rocketed 45% on new copper and gold finds

The micro-cap ASX miner is hitting some rich mineral veins in the Northern Territory.

Read more »